Accelerating Medicines Partnership - Schizophrenia (AMP SCZ) Data Repository

The National Institutes of Health (NIH) is launching a new public-private partnership to accelerate the development of promising therapies for those at risk of developing schizophrenia (SCZ). Part of the Accelerating Medicines Partnership (AMP), AMP SCZ brings together NIH, the U.S. Food and Drug Administration (FDA), and multiple biopharmaceutical, life science, academic, and not-for-profit organizations with the shared goal of discovering better ways of identifying and treating those at clinical high risk for psychosis. The National Institute of Mental Health (NIMH) joins fellow NIH Institutes supporting AMP programs. AMP SCZ adds to ongoing NIMH efforts focused on early detection and intervention in SCZ.